BBOT
BridgeBio Oncology Therapeutics, Inc. · Healthcare · Biotechnology
Last
$10.02
−$0.23 (−2.28%) 4:00 PM ET
Prev close $10.25
Open $10.25
Day high $10.31
Day low $9.93
Volume 148,408
Avg vol 277,931
Mkt cap
$802.29M
P/E ratio
0.00
FY Revenue
$9.79K
EPS
4,922.07
Gross Margin
100.00%
Sector
Healthcare
AI report sections
BBOT
BridgeBio Oncology Therapeutics, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−54% (Below avg)
Vol/Avg: 0.46×
RSI
41.18 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.01 Signal: 0.01
Short-Term
-0.06 (Weak)
MACD: -0.47 Signal: -0.41
Long-Term
-0.10 (Weak)
MACD: -0.58 Signal: -0.47
Intraday trend score 19.00

Latest news

BBOT 3 articles Positive: 3 Neutral: 0 Negative: 0
Positive GlobeNewswire Inc. • Bridgebio Oncology Therapeutics
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

BridgeBio Oncology Therapeutics announced two poster presentations for BBO-10203, a novel small molecule targeting RAS and PI3Kα interactions in cancer treatment, at the San Antonio Breast Cancer Symposium in December 2025.

BBOT BBO-10203 RAS PI3Kα breast cancer oncology molecular targets
Sentiment note

Company is presenting promising preclinical data for a novel cancer therapeutic approach with potential broad applicability across multiple cancer types

Positive GlobeNewswire Inc. • Bridgebio Oncology Therapeutics, Inc.
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

BridgeBio Oncology Therapeutics presented preclinical data on BBO-10203, a novel RAS:PI3Kα breaker that inhibits KRAS-mutant tumor growth without causing hyperglycemia, showing promising results in monotherapy and combination treatments with KRAS inhibitors.

BBOT oncology cancer therapeutics KRAS inhibitors PI3Kα preclinical research
Sentiment note

Presented promising preclinical data demonstrating a novel cancer therapeutic approach with potential to address significant unmet medical needs in cancer treatment

Positive GlobeNewswire Inc. • Globe Newswire
BBOT to Participate in Upcoming September Investor Healthcare Conferences

BridgeBio Oncology Therapeutics (BBOT) announced participation in two investor conferences in September, focusing on presenting their clinical-stage biopharmaceutical work targeting RAS-pathway malignancies.

BBOT oncology biopharmaceutical RAS-pathway clinical-stage investor conferences
Sentiment note

Company is presenting at investor conferences, indicating growth potential and investor interest in their novel small molecule therapeutics targeting cancer-related oncogenes

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal